Shahid Ahmad

Health Science Insider™ (OBIO Strategic Review: July 2016)

2016 has already been a productive year for OBIO as we push forward on our advocacy efforts, expand our Health Science networks and partnerships and continue to provide access to capital for Ontario Health Science companies in order for them to reach the next level. 

Gail Garland, CEO


For the full strategic review, click here

OBIO® Report: Canadian health industry competitive but doesn't stand out

OBIO is a not-for-profit organization committed to the development of an integrated health innovation economy for the province. Its report, How Canada Should be Engaging in a $9 Trillion Dollar Health Economy, was based on surveys and interviews with 125 CEOs of health science companies around the country. It makes recommendations aimed to ensure Canadians get the economic and patient benefits from being competitive in the global health market.


On Tuesday June 16, 2016 the first steps began towards the development of a Canadian National Inclusive Innovation Agenda. In a joint announcement the Minister of Innovation Science and Economic Development, Minister of Science, and the Minister of Small Business and Tourism unveiled 6 action areas to build an innovative Canada. 

Federal Budget Misses Opportunity to Scale and Grow Health Science Companies

The 2016 Federal Liberal budget contains funding to support a much needed Innovation Agenda and promises to build globally competitive companies. At the same time the majority of this funding is directed to incubators and accelerators, granting councils and public institutions to support basic research. In order to compete in the $9 trillion global health science economy, Canada needs to devote financial resources to health science companies at the next stage of development by investing in scale up, job creation and revenue generation. 

Click here to read the article online

OBIO Strategic Review: December 2015

An organization's ability to learn, and translate that learning into action rapidly, is the ultimate competitive advantage.
Jack Welch

As we come to the end of 2015, OBIO is proud of a year that has been characterized by recognition and support from our partners and sponsors, new learnings from the extensive feedback we received during our industry consultations and a very busy schedule as we delivered on programming and advocacy work.

Click here to read the article online

OBIO® Strategic Review: August 2015

They always say time changes things, but you actually have to change them yourself. 
Andy Warhol

2015 has been a year of growth and opportunity for OBIO with expanding networks and new partnerships. Since we released our five year strategic review in January 2015, there have been significant developments both within our walls and across the ecosystem.

Click here to read the article online

OBIO / OBEST Five Year Strategic Review

“The best way to predict the future is to create it”

Peter Drucker

Since its founding in 2009, the Ontario Bioscience Innovation Organization (OBIO®) has been engaged in creating the future of Ontario’s biomedical sector through industry-led strategy, policy development, advocacy and high impact programming. OBIO pursues innovative thought leadership within a culture of trust, reaching out to ever growing circles of thinkers and stakeholders.

Read the article online

Biotechnology Focus article: OBIO® receives investment from the government of Canada to boost investment opportunities and strengthen innovation for Ontario’s commercial bioscience cluster

On May 22, 2015, Member of Parliament for Don Valley West John Carmichael, along with Member of Parliament for Etobicoke-Lakeshore Bernard Trottier announced an investment of up to $3.894 million to support the Ontario Bioscience Innovation Organization’s (OBIO®) efforts to boost investment opportunities for Ontario companies and strengthen innovation for Ontario’s
commercial bioscience cluster.

Click here to view the article online

OBEST Strategic Implementation Plan

Why do we need a strategy? Ontario taxpayers currently spend over $44 billion annually on healthcare and $22 billion for education. The 5% projected rate of increase in (2011/12), healthcare spending is greater than the projected rate of increase for Ontario’s GDP, 2.4% (2011). The education system and academic research funding costs also continue to rise. Ontario is a leading global jurisdiction for innovation indicators, in terms of R&D spending to GDP ratio, and percentage of individuals with post-secondary training. However, Ontarians do not reap the
benefits of an innovation economy due to the underdevelopment of the biosciences industry sector. Our investments in research, novel commercial technologies, highly-qualified individuals, and smaller start-up corporations are, for the most part, lost to foreign markets. The commercial products and services developed from our innovations are then bought back by Ontarians (in the form of novel therapeutics, diagnostics, and devices) at considerable mark-up. The increased costs are not only a growing burden for tax payers, but more importantly, we as Ontarians have not benefited from the economic prosperity (jobs and wealth creation) that would result from a strong and sustainable domestic biosciences sector.

For the full report, click here